bioMérieux S.A. (EPA:BIM)

Market Cap	13.01B
Revenue (ttm)	4.12B
Net Income (ttm)	377.90M
Shares Out	118.07M
EPS (ttm)	3.17
PE Ratio	34.76
Forward PE	22.99
Dividend	0.90 (0.83%)
Ex-Dividend Date	Jun 9, 2025

Volume	71,771
Average Volume	105,310
Open	108.70
Previous Close	108.80
Day's Range	108.70 - 110.60
52-Week Range	95.90 - 128.30
Beta	0.48
RSI	39.36
Earnings Date	Oct 30, 2025

About bioMérieux

bioMérieux S.A. develops and markets in vitro diagnostic solutions for infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It offers CHROMID RANGE, a chromogen culture media; RAPIDEC CARBA NP biochemical test for the detection of carbapenemase producing bacteria; air, surface, and water monitoring systems; BACT/ALERT VIRTUO or 3D, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction system; BIOFIRE SPOTFIRE Lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VI...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1963
• Employees: 14,754
• Stock Exchange: Euronext Paris
• Ticker Symbol: BIM

Financial Performance

In 2024, bioMérieux's revenue was 3.98 billion, an increase of 8.31% compared to the previous year's 3.67 billion. Earnings were 432.20 million, an increase of 20.86%.